Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267).
Questions
1. What are the major unmet needs in current neoadjuvant chemotherapy regimes for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer? (0:06)
2. Could you give us a brief overview of the TRAIN-2 study and its major findings? (1:08)
3. What have the long-term findings of this study taught us about the use of anthracyclines? (4:56)
4. What questions will the TRAIN-3 study address? (5:48)
5. What other approaches should be investigated in this treatment setting? (7:10)
Speaker disclosure: Anna van der Voort has no financial or non-financial relationships or activities to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
